Radio-protective effect of sodium meclofenamate. A prospective clinical trial.
Twentyfour patients treated with irradiation to either their pelvis or their chest for neoplastic disease were included in a randomized study of radioprotection with sodium meclofenamate (Meclomen) (SM). Seventeen patients received SM 100 mg, p.os, t.i.d., and seven received placebo. The long-range radiation related chronic gastrointestinal and urinary tract toxicity was diminished by SM. At 12 months post irradiation, SM treated patients experienced less gastrointestinal and urinary symptoms, as well as less measured bladder contraction, than the controls. Acute gastrointestinal signs of radiotoxicity, however, seemed to have been enhanced by SM. The treated patients suffered from nausea, vomiting, and diarrhea. These acute toxic effects were temporary and reversible.
Mahafzah
M
M
Department of Medicine, Sisters of Charity Hospital, Buffalo, NY 14214.
Halpern
J
J
Nava
H R
HR
Huben
R P
RP
Sayyid
S
S
Bryson
W
W
Ambrus
J L
JL
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D004064:Digestive System / Q000187:drug effects / Q000528:radiation effects; D004311:Double-Blind Method; D006801:Humans; D008469:Meclofenamic Acid / Q000627:therapeutic use*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011446:Prospective Studies; D011832:Radiation Injuries / Q000517:prevention & control; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D001743:Urinary Bladder / Q000187:drug effects / Q000528:radiation effects; D062367:ortho-Aminobenzoates / Q000627:therapeutic use*
D011837:Radiation-Protective Agents; D062367:ortho-Aminobenzoates; D008469:Meclofenamic Acid